Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPX-101 in advanced or refractory solid tumors
NCT05231733Phase 1Withdrawn
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of SPX-101 in solid tumor. Primary endpoints: Maximum Tolerated Dose or Maximum Administered Dose and Safety and Tolerability of SPX-101. Planned start May 2022; status: withdrawn.
02
Drugs
SPX-101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05231733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231733.